Interleukin 2 therapy in cancer: identification of responders. by Broom, J. et al.
Br. J. Cancer (1992), 66, 1185 1187
SHORT COMMUNICATION
Interleukin 2 therapy in cancer: identification of responders
J. Broom', S.D. Heys2, P.H. Whiting', K.G.M. Park2, A. Strachan', I. Rothnie', C.R. Franks3 &
0. Eremin2
Departments of 'Clinical Biochemistry and 2Surgery, University ofAberdeen, Scotland, and 3Eurocetus B. V. Paasheuvelweg 30,
1105J Amsterdam, The Netherlands.
Summary C-reactive protein (CRP) levels in serum were measured in fifteen patients with metastatic
colorectal carcinoma, prior to and during treatment with a continuous intravenous infusion of rIL.2. Patients
were subsequently classified as responders or non-responders to this therapy. Baseline serum CRP levels, prior
to treatment, were significantly lower in the responders (range <2-8 mg- 1) when compared with the
non-responders (range 7.5-116 mg 1'), P = 0.004. Furthermore, the responding patients demonstrated
significantly and grossly elevated CRP stimulation indices (SI) compared with non-responders at different time
intervals during the rIL2 infusion. At the cessation of rIL2 therapy, the CRP stimulation index was 31.3 ± 9.3
in the responders, and only 1.6 ± 0.3 in the non-responders (means ± s.e.m, P = 0.014). These findings suggest
that it is possible to predict those cancer patients who are most likely to respond to and benefit from rIL2
therapy, either prior to the commencement of or during the first course of rIL2.
New strategies in the treatment of cancer have centred on the
use of Biological Response Modifiers, and, in particular,
recombinant interleukin 2 (rIL2). Although rIL2 has been
successful in the treatment of malignancy in animal models,
subsequent clinical studies in man have shown that in suscep-
tible solid cancers - metastatic melanoma and renal cell
carcinoma - partial or complete responses to therapy occur
in only 25-30% of patients and with a substantial morbidity
(West et al., 1987; Rosenberg et al., 1989). It is, therefore,
not surprising that attempts have been made to predict, at an
early stage of therapy, which patients will subsequently re-
spond to rIL2 therapy, but to date, it has not been possible
to clearly identify these patients.
Interest has focused on the function of the acute phase
proteins in inflammation and malignancy. Of the latter pro-
teins, C-reactive protein (CRP) has been identified as a sen-
sitive, specific and rapidly responsive protein in serum
(Weinstein et al., 1984). CRP has been shown to be induced
by various malignancies, including different types of
adenocarcinomas, and its level in serum to be elevated in
patients with metastatic disease (Weinstein et al., 1984). We
present preliminary data showing that CRP levels in serum
may also be used as predictors of response to treatment with
rIL2.
Materials and methods
Fifteen patients with metastatic colorectal cancer were
treated with rIL2 (18 x 106 IU m2 body surface area/24 h), by
continuous intravenous infusion for a total of 120 h, com-
bined with three pulses of 5-fluorouracil (600mg/M2 body
surface area), and folinic acid, (25 mg/M2 body surface area),
also given intravenously at weekly intervals, starting 48 h
after completing the rIL2 infusion. Prior to commencing any
treatment, the concentrations of CRP were measured in the
patients serum by rate nephelometry (Stemnberg, 1977), using
a Beckman ICS Analyser II with Beckman reagents, cali-
brators and controls (CRP standardised against WHO CRP
standard). The coefficient of variation for CRP measure-
ments is 4% in our laboratory and the lower limit of the
assay was 2 mg 1-. In addition, the serum concentrations of
CRP during therapy were measured at 12 h, 24 h, 48 h, 72 h
and 120 h after the commencement of the rIL2 infusions.
The metastatic tumours were assessed by ultrasound, CT
radiography and MRI scanning (4 weeks after the start of
treatment and subsequently at monthly intervals). If the
disease was static or had responded (partial response was
defined as a reduction of greater than 50% in tumour
measurements carried out in two perpendicular planes; com-
plete response was no tumour detected by imaging
modalities), further therapy was given, as described above, to
a maximum of six cycles.
The patients data was grouped into (i) responders (partial
or complete) and (ii) non-responders (stasis or progression of
disease), to treatment. The pre-treatment CRP levels were
compared using Fischers exact test, and the time courses
analysed using a Mann-Whitney U test to compare mean
values at each time interval.
Results
Six patients responded (1 complete and 5 partial responders)
and 9 patients failed to demonstrate any response, to rIL2
therapy; their relevant details and serum concentrations of
CRP, before treatment was started, are shown in Table I.
The 95th percentile for serum CRP levels in normal indivi-
duals in our laboratory is 10 mg 1-', and Table II shows that
all responders had levels of less than 10 mg 1' range,
<2-8 mgI ', and that seven out of eight non-responders
had serum concentrations of greater than 1Omg I` (range,
8-116mgl-'), P=0.004.
The time-course for the two groups, responders and non-
responders, is shown in Figure 1. These are expressed as a
Stimulation Index (SI) for time 't', (e.g. 12-72 h)
SI = CRP serum concentration at 't'
pre-treatment CRP concentration
The responders demonstrated a SI which rose substantially
throughout the rIL2 infusion, from a pretreatment value of 1
to 31.3 ± 9.3 (mean ± s.e.m.) at the end of the infusion. In
comparison, the pretreatment SI in the non-responding
patients was 1, and demonstrated a minimal increase only
during treatment, and was still only 1.6 ± 0.3 (mean ± s.e.m.)
at the end of the rIL2 infusion. At all time intervals when
CRP was measured during rIL2 infusion, the SI was
significantly higher in the responding patients than in the
non-responding patients (P = 0.014). One of the non-
responding patients, (GR), had a low CRP level prior to the
start of therapy, but the time course values for the CRP
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Table I Clinical details and pre-treatment serum CRP levels in patients treated with rIL2
Pre-treatment
Patient Age Sex Site of metastases Response to rIL2 CRP (mgI-')
JW 63 m liver no response 52
JW 54 m liver complete response 8
DM 70 m liver no response 116
GR 53 m liver no response 8
JC 63 f lymph nodes partial response 3
FH 52 m liver no response 51
EQ 73 f liver no response 115
EB 69 f liver partial response 7
AJ 65 m liver no response 63
ET 60 f lymph nodes partial response 4
IW 58 m liver no response 74
JJ 68 m liver no response 45
GM 38 f lymph nodes partial response 2
GK 68 m liver partial response 4
CS 38 m liver no response 110




Responders (n = 6) 0 6
Range (mgI-') - <2-8
Non-responders (n = 9) 8 1
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Figure 1 The time course for the CRP response during rIL2
infusion for 120 h. Values shown are means + s.e.m., with all
time points being significantly higher in the responding patients.
levels during the rIL2 infusion were similar to the other
non-responders.
Discussion
The acute phase protein, CRP, is one of thirty or more
proteins produced by the liver in response to tissue damage
and inflammation associated with infections, chronic disease
states and malignant disease (Weinstein et al., 1984; Kushner,
1982). Although different roles, such as inflammatory
mediators, scavengers and enzyme inhibitors, have been as-
cribed to some of these proteins, the precise function of CRP
remains to be elucidated. Nevertheless, it is a sensitive and
relatively specific marker for monitoring inflammatory condi-
tions, particularly those associated with significant tissue
damage. In malignant disease, a high or rising level of serum
CRP has been associated with a large tumour volume and
dissemination, and poor prognosis (Weinstein et al., 1984).
The cytokines, ILl, IL6 and tumour necrosis factor (TNF),
are believed to play a crucial role in the control of acute
phase protein synthesis in the liver, by gene regulation
(Dinarello, 1984; Baumann et al., 1987; Marinkovic et al.,
1989).
Our data show that a response (partial or complete) to
rIL2 occurred only in those patients whose serum CRP was
less than 10mg1'. In contrast, patients who failed to re-
spond (stasis or progression of disease) to rIL2 therapy had
CRP values which were grossly elevated, with the exception
of one patient who had baseline levels. The reasons for the
substantial pre-treatment difference between responding and
non-responding patients remain unclear. All patients in this
study had metastatic adenocarcinoma and three of the six
responding patients had comparable tumour loads to those
of the non-responding group of patients. However, the high
baseline levels of CRP may be a reflection of either tumour
burden or biological aggressiveness and hence enhanced
tumour cell turnover (no patient had evidence of concurrent
infection). The elevated levels of CRP induced by rIL2 in the
responders may be a measure of cytokine release, in partic-
ular TNF, and subsequent beneficial anti-cancer response.
Indeed, Blay et al. (1990) showed a correlation between
sustained production of TNF and clinical response to rIL2.
It is also important to note that the non-responding patient
who had low baseline CRP levels (which can occur in
patients with extensive tumour deposits) conformed to the
pattern shown by all other non-responders, i.e. in failing to
demonstrate a CRP response during the rIL2 infusion.
Thus, in assessing patients as to their suitability for con-
tinuous intravenous rIL2 therapy, with its associated mor-
bidity and expense, it is apparent that patients who are
already demonstrating a significant acute phase response, as
demonstrated by increased circulating concentrations of
CRP, are unlikely to respond to this treatment. Whilst
patients with low baseline levels of CRP, in conjunction with
the ability to mount a substantially enhanced CRP response
during rIL2 infusion, should be selected for active and pos-
sibly prolonged treatment. Further careful studies are needed
to confirm these findings and to elucidate the possible under-
lying mechanisms of anti-cancer activity.
We are grateful to Eurocetus for supplying the rIL2.
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